{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:34:24Z","timestamp":1782765264104,"version":"3.54.5"},"reference-count":106,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Istituto Superiore di Sanit\u00e0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Amyotrophic lateral sclerosis (ALS) is a rare progressive motor neuron disease that, due to its high complexity, still lacks effective treatments. Development of a new drug is a highly costly and time-consuming process, and the repositioning of approved drugs can represent an efficient strategy to provide therapeutic opportunities. This is particularly true for rare diseases, which are characterised by small patient populations and therefore attract little commercial interest. Based on the overlap between the biological background of cancer and neurodegeneration, the repurposing of antineoplastic drugs for ALS has been suggested. The objective of this narrative review was to summarise the current experimental evidence on the use of approved anticancer drugs in ALS. Specifically, anticancer drugs belonging to different classes were found to act on mechanisms involved in the ALS pathogenesis, and some of them proved to exert beneficial effects in ALS models. However, additional studies are necessary to confirm the real therapeutic potential of anticancer drugs for repositioning in ALS treatment.<\/jats:p>","DOI":"10.3390\/ijms25031751","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T08:44:08Z","timestamp":1706777048000},"page":"1751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-0705","authenticated-orcid":false,"given":"Rosa Luisa","family":"Potenza","sequence":"first","affiliation":[{"name":"National Centre for Drug Research and Evaluation, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Armida","sequence":"additional","affiliation":[{"name":"National Centre for Drug Research and Evaluation, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Popoli","sequence":"additional","affiliation":[{"name":"National Centre for Drug Research and Evaluation, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/21678421.2021.2004167","article-title":"Trends in survival of ALS from a population-based registry","volume":"23","author":"Bianchi","year":"2022","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00415-019-09652-y","article-title":"Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"267","author":"Xu","year":"2020","journal-title":"J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"596006","DOI":"10.3389\/fneur.2021.596006","article-title":"Destination Amyotrophic Lateral Sclerosis","volume":"12","author":"Keon","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/1673-5374.244783","article-title":"Amyotrophic lateral sclerosis: A complex syndrome that needs an integrated research approach","volume":"14","author":"Riancho","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: Translating genetic discoveries into therapies","volume":"24","author":"Lopez","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_7","first-page":"99","article-title":"The emerging picture of ALS: A multisystem, not only a \u201cmotor neuron disease\u201d","volume":"155","author":"Silani","year":"2017","journal-title":"Arch. Ital. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/bib\/bbr021","article-title":"Drug repositioning for orphan diseases","volume":"12","author":"Sardana","year":"2011","journal-title":"Brief. Bioinform."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"D1060","DOI":"10.1093\/nar\/gkq1037","article-title":"PROMISCUOUS: A database for network-based drug-repositioning","volume":"39","author":"Murgueitio","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mogavero, M.P., Silvani, A., DelRosso, L.M., Salemi, M., and Ferri, R. (2021). Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity. Cancers, 13.","DOI":"10.3390\/cancers13112612"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00018-019-03428-3","article-title":"Molecular crosstalk between cancer and neurodegenerative diseases","volume":"77","author":"Seo","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4103\/1673-5374.208569","article-title":"Repurposing cancer drugs to treat neurological diseases\u2014Src inhibitors as examples","volume":"12","author":"Liu","year":"2017","journal-title":"Neural Regen. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104841","DOI":"10.1016\/j.neuint.2020.104841","article-title":"Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach","volume":"140","author":"Advani","year":"2020","journal-title":"Neurochem. Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Potenza, R.L., Lodeserto, P., and Orienti, I. (2022). Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137426"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/bph.15151","article-title":"Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge","volume":"178","author":"Riancho","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Taguchi, Y.H., and Wang, H. (2017). Genetic Association between Amyotrophic Lateral Sclerosis and Cancer. Genes, 8.","DOI":"10.3390\/genes8100243"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1074\/jbc.C113.526475","article-title":"SOD2 to SOD1 switch in breast cancer","volume":"289","author":"Papa","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2741\/4777","article-title":"Cancer-related genes and ALS","volume":"24","author":"Yamamoto","year":"2019","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2018.08.013","article-title":"Clinical evidences supporting the Src\/c-Abl pathway as potential therapeutic target in amyotrophic lateral sclerosis","volume":"393","author":"Riancho","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological roles of MAPK signaling pathways in human diseases","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41419-018-0624-8","article-title":"Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS","volume":"9","author":"Gibbs","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/21678421.2013.775309","article-title":"Amyotrophic lateral sclerosis and cancer: A register-based study in Sweden","volume":"14","author":"Fang","year":"2013","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10552-012-0089-5","article-title":"The association between cancer and amyotrophic lateral sclerosis","volume":"24","author":"Freedman","year":"2013","journal-title":"Cancer Causes Control"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1212\/WNL.0000000000002757","article-title":"Population-based risks for cancer in patients with ALS","volume":"87","author":"Gibson","year":"2016","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0277-5379(91)90309-2","article-title":"Long-term tolerability of fenretinide (4-HPR) in breast cancer patients","volume":"27","author":"Rotmensz","year":"1991","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_27","unstructured":"European Medicines Agency (2024, January 15). EU\/3\/06\/426: Public Summary of Positive Opinion for Orphan Designation of Fenretinide for the Treatment of Primary Malignant Bone Tumours. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu306426-public-summary-positive-opinion-orphan-designation-fenretinide-treatment-primary-malignant-bone-tumours_en.pdf."},{"key":"ref_28","unstructured":"European Medicines Agency (2024, January 15). EU\/3\/16\/1751: Public Summary of Positive Opinion for Orphan Designation of Fenretinide for the Treatment of Peripheral T-Cell Lymphoma. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20161014136138\/dec_136138_en.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2021.07.033","article-title":"Fenretinide Beneficial Effects on Amyotrophic Lateral Sclerosis-associated SOD1G93A Mutant Protein Toxicity: In Vitro and In Vivo Evidences","volume":"473","author":"Orienti","year":"2021","journal-title":"Neuroscience"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1089\/ars.2013.5446","article-title":"The Oxidation States of DJ-1 Dictate the Cell Fate in Response to Oxidative Stress Triggered by 4-HPR: Autophagy or Apoptosis?","volume":"21","author":"Cao","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kim, Y.-K., and Hammerling, U. (2020). The mitochondrial PKC\u03b4\/retinol signal complex exerts real-time control on energy homeostasis. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1865.","DOI":"10.1016\/j.bbalip.2020.158614"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, Recognition, and Processing of Cisplatin-DNA Adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/anie.200502599","article-title":"Structural investigation of cisplatin-protein interactions: Selective platination of His19 in a cuprozinc superoxide dismutase","volume":"45","author":"Calderone","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1073\/pnas.0705044104","article-title":"Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis","volume":"104","author":"Gruzman","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1093\/hmg\/ddq408","article-title":"An examination of wild-type SOD1 in modulating the toxicity and aggregation of ALS-associated mutant SOD1","volume":"19","author":"Prudencio","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1073\/pnas.1207493109","article-title":"Human superoxide dismutase 1 (hSOD1) maturation through interaction with human copper chaperone for SOD1 (hCCS)","volume":"109","author":"Banci","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1074\/jbc.M705657200","article-title":"Cysteine 111 affects aggregation and cytotoxicity of mutant Cu,Zn-superoxide dismutase associated with familial amyotrophic lateral sclerosis","volume":"283","author":"Cozzolino","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12031-020-01551-6","article-title":"The Cysteine (Cys) Residues Cys-6 and Cys-111 in Mutant Superoxide Dismutase 1 (SOD1) A4V Are Required for Induction of Endoplasmic Reticulum Stress in Amyotrophic Lateral Sclerosis","volume":"70","author":"Perri","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1021\/ja211591n","article-title":"Interaction of cisplatin with human superoxide dismutase","volume":"134","author":"Banci","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_42","first-page":"145","article-title":"New Targeting in the Reversal of Resistant Glioblastomas","volume":"Volume 14","author":"Arbab","year":"2021","journal-title":"Cancer Sensitizing Agents for Chemotherapy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.celrep.2017.02.001","article-title":"Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment","volume":"18","author":"Lu","year":"2017","journal-title":"Cell Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nardo, G., Pozzi, S., Pignataro, M., Lauranzano, E., Spano, G., Garbelli, S., Mantovani, S., Marinou, K., Papetti, L., and Monteforte, M. (2011). Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025545"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17482960701702553","article-title":"Association study on glutathione S-transferase omega 1 and 2 and familial ALS","volume":"9","author":"Fogh","year":"2008","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1474-4422(10)70195-2","article-title":"TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"9","author":"Mackenzie","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cha, S.J., Han, Y.J., Choi, H.J., Kim, H.J., and Kim, K. (2020). Glutathione S-Transferase Rescues Motor Neuronal Toxicity in Fly Model of Amyotrophic Lateral Sclerosis. Antioxidants, 9.","DOI":"10.3390\/antiox9070615"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.devcel.2022.02.022","article-title":"Therapeutic modulation of GSTO activity rescues FUS-associated neurotoxicity via deglutathionylation in ALS disease models","volume":"57","author":"Cha","year":"2022","journal-title":"Dev. Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0006-2952(97)00040-3","article-title":"An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug","volume":"53","author":"Ghoshal","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rando, A., de la Torre, M., Martinez-Muriana, A., Zaragoza, P., Musaro, A., Hern\u00e1ndez, S., Navarro, X., Toivonen, J.M., and Osta, R. (2019). Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210752"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pokrishevsky, E., Hong, R.H., Mackenzie, I.R., and Cashman, N.R. (2017). Spinal cord homogenates from SOD1 familial amyotrophic lateral sclerosis induce SOD1 aggregation in living cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184384"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nbd.2018.11.025","article-title":"Tryptophan 32 mediates SOD1 toxicity in a in vivo motor neuron model of ALS and is a promising target for small molecule therapeutics","volume":"124","author":"DuVal","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1028-4559(08)60051-0","article-title":"The role of selective estrogen receptor modulators on breast cancer: From tamoxifen to raloxifene","volume":"47","author":"Lee","year":"2008","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.4103\/1673-5374.189164","article-title":"Tamoxifen: An FDA approved drug with neuroprotective effects for spinal cord injury recovery","volume":"11","author":"Miranda","year":"2016","journal-title":"Neural Regen. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1742-2094-10-157","article-title":"Tamoxifen as an effective neuroprotectant against early brain injury and learning deficits induced by subarachnoid hemorrhage: Possible involvement of inflammatory signaling","volume":"10","author":"Sun","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"15024","DOI":"10.1073\/pnas.1206362109","article-title":"Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43","volume":"109","author":"Wang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e20423","DOI":"10.1097\/MD.0000000000020423","article-title":"Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/21678421.2019.1682613","article-title":"Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12031-011-9588-1","article-title":"c-Abl in neurodegenerative disease","volume":"45","author":"Schlatterer","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.7150\/ijms.73740","article-title":"Roles for c-Abl in postoperative neurodegeneration","volume":"19","author":"Feng","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ana.20379","article-title":"Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis","volume":"57","author":"Jiang","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Katsumata, R., Ishigaki, S., Katsuno, M., Kawai, K., Sone, J., Huang, Z., Adachi, H., Tanaka, F., Urano, F., and Sobue, G. (2012). c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046185"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: Progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.phrs.2019.03.014","article-title":"Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord","volume":"143","author":"Kumar","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fncel.2015.00203","article-title":"Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling","volume":"9","author":"Rojas","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.0022-202X.2004.22231.x","article-title":"Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo","volume":"122","author":"McGary","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eaaf3962","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"eaat5847","DOI":"10.1126\/sciadv.aat5847","article-title":"Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons","volume":"4","author":"Osaki","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/emmm.201302771","article-title":"Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance","volume":"5","author":"Lonskaya","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e033131","DOI":"10.1136\/bmjopen-2019-033131","article-title":"Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: Protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients","volume":"9","author":"Imamura","year":"2019","journal-title":"BMJ Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.eclinm.2022.101707","article-title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial","volume":"53","author":"Imamura","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Cast\u00e9ran, N., Borge, L., Hajem, B., Lermet, A., and Sippl, W. (2009). Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007258"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Vermersch, P., Benrabah, R., Schmidt, N., Z\u00e9phir, H., Clavelou, P., Vongsouthi, C., Dubreuil, P., Moussy, A., and Hermine, O. (2012). Masitinib treatment in patients with progressive multiple sclerosis: A randomized pilot study. BMC Neurol., 12.","DOI":"10.1186\/1471-2377-12-36"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: A randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e95934","DOI":"10.1172\/jci.insight.95934","article-title":"Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS","volume":"2","author":"Trias","year":"2017","journal-title":"JCI Insight"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e123249","DOI":"10.1172\/jci.insight.123249","article-title":"Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS","volume":"3","author":"Trias","year":"2018","journal-title":"JCI Insight"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/glia.23768","article-title":"Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis","volume":"68","author":"Trias","year":"2020","journal-title":"Glia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40478-021-01241-3","article-title":"The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS","volume":"9","author":"Kovacs","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"AB10015 STUDY GROUP. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17562864211030365","DOI":"10.1177\/17562864211030365","article-title":"Long-term survival analysis of masitinib in amyotrophic lateral sclerosis","volume":"14","author":"Mora","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: A review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: Principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract. Neurol."},{"key":"ref_84","first-page":"CD013247","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/21678421.2022.2122845","article-title":"ALSUntangled #67: Rituximab","volume":"24","author":"Li","year":"2023","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_86","first-page":"2416","article-title":"Vincristine-induced peripheral neuropathy in pediatric cancer patients","volume":"6","author":"Mora","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13346-023-01389-6","article-title":"Vincristine-based nanoformulations: A preclinical and clinical studies overview","volume":"14","author":"Shukla","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000077888","article-title":"Chemotherapy delays progression of motor neuron disease in the SOD1 G93A transgenic mouse","volume":"50","author":"Bruce","year":"2004","journal-title":"Chemotherapy"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Lien, L.M., Lu, W.J., Lin, K.H., Kang, L.H., Chen, T.Y., Lin, B.J., Lu, Y.C., Huang, C.Y., Shih, C.M., and Chen, H. (2021). Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets. Molecules, 26.","DOI":"10.3390\/molecules26175340"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1939-1676.1996.tb02052.x","article-title":"Canine idiopathic thrombocytopenic purpura","volume":"10","author":"Lewis","year":"1996","journal-title":"J. Vet. Intern. Med."},{"key":"ref_91","first-page":"40","article-title":"Structure of peripheral blood platelets surface in patients with amyotrophic lateral sclerosis and multiple sclerosis","volume":"105","author":"Kiktenko","year":"2005","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/00207454.2010.537416","article-title":"Mitochondrial perturbance and execution of apoptosis in platelet mitochondria of patients with amyotrophic lateral sclerosis","volume":"121","author":"Shrivastava","year":"2011","journal-title":"Int. J. Neurosci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1086\/315754","article-title":"Effect of thalidomide on chemokine production by human microglia","volume":"182","author":"Lokensgard","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Kopp, K.O., Greer, M.E., Glotfelty, E.J., Hsueh, S.C., Tweedie, D., Kim, D.S., Reale, M., Vargesson, N., and Greig, N.H. (2023). A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules, 13.","DOI":"10.3390\/biom13050747"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1523\/JNEUROSCI.5253-05.2006","article-title":"Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"26","author":"Kiaei","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.expneurol.2009.08.028","article-title":"Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis","volume":"220","author":"Neymotin","year":"2009","journal-title":"Exp. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/17482960802709416","article-title":"Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial","volume":"10","author":"Stommel","year":"2009","journal-title":"Amyotroph Lateral Scler."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0048-9697(82)90066-3","article-title":"Hormesis\u2014The stimulation of growth by low levels of inhibitors","volume":"22","author":"Stebbing","year":"1982","journal-title":"Sci. Total Environ."},{"key":"ref_101","first-page":"5851","article-title":"A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents","volume":"35","author":"Yoshimasu","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1021\/acs.jcim.9b00031","article-title":"Extended Multitarget Pharmacology of Anticancer Drugs","volume":"59","author":"Shi","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e071726","DOI":"10.1136\/bmj-2022-071726","article-title":"Cognitive impairment after cancer treatment: Mechanisms, clinical characterization, and management","volume":"380","author":"Fleming","year":"2023","journal-title":"BMJ"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s13311-021-01064-z","article-title":"Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis","volume":"18","author":"Fiscon","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","article-title":"Phenotypic drug discovery: Recent successes, lessons learned and new directions","volume":"21","author":"Vincent","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:52:51Z","timestamp":1760104371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":106,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031751"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031751","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}